(L)-2-oxothiazolidine-4-carboxylate in the treatment of primary hyperoxaluria type 1

R. P. Holmes, D. G. Assimos, D. M. Wilson, D. S. Milliner

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objective: To evaluate the short-term efficacy of (L)-2-oxothiaolidine-4-carboxylate (OTZ, which reduces urinary oxalate excretion in normal subjects) in the treatment of primary hyperoxaluria type 1 (PH1) in a phase II study. Patients and methods: Two patients with PH1 received intravenous infusions of OTZ (100 mg/kg body weight for 2 h) given every 8 h for four doses. One patient also received a placebo treatment. Urine samples (24-h collections) were obtained before and during OTZ treatment and assayed for oxalate, citrate, creatinine, sulphate and pH. Daily blood samples were assayed for plasma oxalate and serum creatinine. Results: Urinary oxalate excretion was unaffected by OTZ treatment. Plasma oxalate declined in both individuals with OTZ treatment, but the effect was small. Plasma cysteine was normal in one patient, rising from a mean (SD) of 36 (3.7) μmol/L before treatment to a peak of 141 μmol/L after OTZ, but was not detected in samples from the other patient. The ratio of oxalate to creatinine clearances was high in both patients, with mean values of 3.1 and 3.8. Conclusions: Treatment with OTZ did not lead to clinically significant changes in urinary oxalate excretion. The high clearance of oxalate in these patients suggests a substantial renal secretion of oxalate.

Original languageEnglish (US)
Pages (from-to)858-862
Number of pages5
JournalBJU International
Volume88
Issue number9
DOIs
StatePublished - 2001

Fingerprint

Oxalates
Creatinine
Therapeutics
Primary hyperoxaluria type 1
2-oxothiazolidine-4-carboxylic acid
Intravenous Infusions
Citric Acid
Sulfates
Cysteine
Placebos
Body Weight
Urine
Kidney

Keywords

  • Inborn errors
  • Kidneys calculi
  • Metabolism
  • Oxalic acid

ASJC Scopus subject areas

  • Urology

Cite this

(L)-2-oxothiazolidine-4-carboxylate in the treatment of primary hyperoxaluria type 1. / Holmes, R. P.; Assimos, D. G.; Wilson, D. M.; Milliner, D. S.

In: BJU International, Vol. 88, No. 9, 2001, p. 858-862.

Research output: Contribution to journalArticle

Holmes, R. P. ; Assimos, D. G. ; Wilson, D. M. ; Milliner, D. S. / (L)-2-oxothiazolidine-4-carboxylate in the treatment of primary hyperoxaluria type 1. In: BJU International. 2001 ; Vol. 88, No. 9. pp. 858-862.
@article{58b2897b99794e0da247e1b37589bc64,
title = "(L)-2-oxothiazolidine-4-carboxylate in the treatment of primary hyperoxaluria type 1",
abstract = "Objective: To evaluate the short-term efficacy of (L)-2-oxothiaolidine-4-carboxylate (OTZ, which reduces urinary oxalate excretion in normal subjects) in the treatment of primary hyperoxaluria type 1 (PH1) in a phase II study. Patients and methods: Two patients with PH1 received intravenous infusions of OTZ (100 mg/kg body weight for 2 h) given every 8 h for four doses. One patient also received a placebo treatment. Urine samples (24-h collections) were obtained before and during OTZ treatment and assayed for oxalate, citrate, creatinine, sulphate and pH. Daily blood samples were assayed for plasma oxalate and serum creatinine. Results: Urinary oxalate excretion was unaffected by OTZ treatment. Plasma oxalate declined in both individuals with OTZ treatment, but the effect was small. Plasma cysteine was normal in one patient, rising from a mean (SD) of 36 (3.7) μmol/L before treatment to a peak of 141 μmol/L after OTZ, but was not detected in samples from the other patient. The ratio of oxalate to creatinine clearances was high in both patients, with mean values of 3.1 and 3.8. Conclusions: Treatment with OTZ did not lead to clinically significant changes in urinary oxalate excretion. The high clearance of oxalate in these patients suggests a substantial renal secretion of oxalate.",
keywords = "Inborn errors, Kidneys calculi, Metabolism, Oxalic acid",
author = "Holmes, {R. P.} and Assimos, {D. G.} and Wilson, {D. M.} and Milliner, {D. S.}",
year = "2001",
doi = "10.1046/j.1464-4096.2001.02439.x",
language = "English (US)",
volume = "88",
pages = "858--862",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - (L)-2-oxothiazolidine-4-carboxylate in the treatment of primary hyperoxaluria type 1

AU - Holmes, R. P.

AU - Assimos, D. G.

AU - Wilson, D. M.

AU - Milliner, D. S.

PY - 2001

Y1 - 2001

N2 - Objective: To evaluate the short-term efficacy of (L)-2-oxothiaolidine-4-carboxylate (OTZ, which reduces urinary oxalate excretion in normal subjects) in the treatment of primary hyperoxaluria type 1 (PH1) in a phase II study. Patients and methods: Two patients with PH1 received intravenous infusions of OTZ (100 mg/kg body weight for 2 h) given every 8 h for four doses. One patient also received a placebo treatment. Urine samples (24-h collections) were obtained before and during OTZ treatment and assayed for oxalate, citrate, creatinine, sulphate and pH. Daily blood samples were assayed for plasma oxalate and serum creatinine. Results: Urinary oxalate excretion was unaffected by OTZ treatment. Plasma oxalate declined in both individuals with OTZ treatment, but the effect was small. Plasma cysteine was normal in one patient, rising from a mean (SD) of 36 (3.7) μmol/L before treatment to a peak of 141 μmol/L after OTZ, but was not detected in samples from the other patient. The ratio of oxalate to creatinine clearances was high in both patients, with mean values of 3.1 and 3.8. Conclusions: Treatment with OTZ did not lead to clinically significant changes in urinary oxalate excretion. The high clearance of oxalate in these patients suggests a substantial renal secretion of oxalate.

AB - Objective: To evaluate the short-term efficacy of (L)-2-oxothiaolidine-4-carboxylate (OTZ, which reduces urinary oxalate excretion in normal subjects) in the treatment of primary hyperoxaluria type 1 (PH1) in a phase II study. Patients and methods: Two patients with PH1 received intravenous infusions of OTZ (100 mg/kg body weight for 2 h) given every 8 h for four doses. One patient also received a placebo treatment. Urine samples (24-h collections) were obtained before and during OTZ treatment and assayed for oxalate, citrate, creatinine, sulphate and pH. Daily blood samples were assayed for plasma oxalate and serum creatinine. Results: Urinary oxalate excretion was unaffected by OTZ treatment. Plasma oxalate declined in both individuals with OTZ treatment, but the effect was small. Plasma cysteine was normal in one patient, rising from a mean (SD) of 36 (3.7) μmol/L before treatment to a peak of 141 μmol/L after OTZ, but was not detected in samples from the other patient. The ratio of oxalate to creatinine clearances was high in both patients, with mean values of 3.1 and 3.8. Conclusions: Treatment with OTZ did not lead to clinically significant changes in urinary oxalate excretion. The high clearance of oxalate in these patients suggests a substantial renal secretion of oxalate.

KW - Inborn errors

KW - Kidneys calculi

KW - Metabolism

KW - Oxalic acid

UR - http://www.scopus.com/inward/record.url?scp=0035698795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035698795&partnerID=8YFLogxK

U2 - 10.1046/j.1464-4096.2001.02439.x

DO - 10.1046/j.1464-4096.2001.02439.x

M3 - Article

C2 - 11851603

AN - SCOPUS:0035698795

VL - 88

SP - 858

EP - 862

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 9

ER -